C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.925
-0.125 (-3.08%)
Nov 21, 2024, 2:59 PM EST - Market open
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 10, with a low estimate of 4.00 and a high estimate of 20. The average target predicts an increase of 154.78% from the current stock price of 3.93.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CCCC stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Buy | 2 | 2 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 8 | 7 | 7 | 7 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Stephens & Co. | Stephens & Co. | Hold Initiates $4 | Hold | Initiates | $4 | +1.91% | Nov 18, 2024 |
BMO Capital | BMO Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +409.55% | Aug 6, 2024 |
Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +103.82% | May 9, 2024 |
Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +256.69% | May 9, 2024 |
Morgan Stanley | Morgan Stanley | Hold Maintains $1 → $8 | Hold | Maintains | $1 → $8 | +103.82% | Feb 26, 2024 |
Financial Forecast
Revenue This Year
36.69M
from 20.76M
Increased by 76.74%
Revenue Next Year
16.37M
from 36.69M
Decreased by -55.37%
EPS This Year
-1.54
from -2.67
EPS Next Year
-1.75
from -1.54
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 42.4M | 31.5M | 38.6M | ||
Avg | 36.7M | 16.4M | 17.7M | ||
Low | 29.4M | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 104.4% | -14.1% | 136.0% | ||
Avg | 76.7% | -55.4% | 8.1% | ||
Low | 41.6% | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -1.51 | -1.48 | -1.40 |
Avg | -1.54 | -1.75 | -1.65 |
Low | -1.58 | -1.86 | -2.20 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.